AVEO Oncology is passionate in our pursuit of improving the lives of patients with cancer.
Find out More
A Phase 3 Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced RCC
Click here for more information
18th Annual Rodman & Renshaw Global Investment Conference
September 12, 2016
2016 JMP Securities Life Science Conference
June 22, 2016
AVEO Oncology Announces Proposed Settlement and Settlement Hearing in 2014 Stockholder Litigation
September 30, 2016
AVEO to Present at the 18th Annual Rodman & Renshaw Global Investment Conference
September 6, 2016
AVEO Initiates the Evaluation of Tivozanib in Combination with Bristol-Myers Squibb’s Opdivo® (nivolumab) in Advanced Renal Cell Carcinoma
August 15, 2016
© 2016 AVEO Pharmaceuticals, Inc. All rights reserved.